NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Price Target & More

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics Inc (NASDAQ:PTI) announced its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.21. The company had revenue of $0.94 million for the quarter, compared to analyst estimates of $1.03 million. Proteostasis Therapeutics had a negative net margin of 1,052.11% and a negative return on equity of 101.44%. View Proteostasis Therapeutics' Earnings History.

4 brokers have issued twelve-month price targets for Proteostasis Therapeutics' shares. Their predictions range from $5.00 to $25.00. On average, they anticipate Proteostasis Therapeutics' share price to reach $13.25 in the next year. This suggests a possible upside of 385.3% from the stock's current price. View Analyst Ratings for Proteostasis Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Proteostasis Therapeutics include Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Xeris Pharmaceuticals (XERS), Savara (SVRA), Mersana Therapeutics (MRSN), MediciNova (MNOV), Clementia Pharmaceuticals (CMTA), Kindred Biosciences (KIN), GTX (GTXI), Paratek Pharmaceuticals (PRTK), Ra Pharmaceuticals (RARX), BioSpecifics Technologies (BSTC), Vital Therapies (VTL), Clearside Biomedical (CLSD) and Bellicum Pharmaceuticals (BLCM).

(PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Media stories about PTI stock have trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 0.15 on Accern's scale. They also gave news stories about the company an impact score of 45.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $2.73.

Proteostasis Therapeutics has a market capitalization of $101.03 million and generates $5.34 million in revenue each year. The company earns $-59,430,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Proteostasis Therapeutics employs 52 workers across the globe.

Proteostasis Therapeutics' mailing address is 80 GUEST STREET 5TH FLOOR, BOSTON MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]